BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery deals with Merck KGaA
Merck KGaA has inked two separate AI drug discovery partnerships with BenevolentAI and Exscientia that are focused on three targets in oncology, neurology and immunology, representing a promising change in direction for the UK-based AI companies.
Exscientia will get $20 million upfront upon starting each of the three projects under a deal worth $674 million across all milestones. BenevolentAI will receive a low double-digit million dollar payment upfront in a deal potentially worth $594 million, and both companies could get tiered royalties on future sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.